Bone Biologics

Bone Biologics is a publicly traded company headquartered in Burlington, Massachusetts, focused on developing and marketing orthobiologic products for spine fusion markets. Their proprietary platform technology is NELL-1, a recombinant human protein growth factor essential for normal bone development. They are currently preparing for pilot clinical trials in Australia and aim to commercialize their technology in the $3 billion orthobiologics market, pending successful completion of pivotal human studies in the United States.

Bone Biologics is committed to exploring additional applications of their NELL-1 technology to enhance bone regeneration and repair in areas where current options are suboptimal. They are actively pursuing applications in trauma and osteoporosis, recognizing the growing burden of musculoskeletal diseases and the need for innovative solutions. The company has strong preclinical data demonstrating the effectiveness of their NELL-1-based products and a lean, virtual business model that allows them to collaborate with strategic partners and vendors to achieve their goals.

Bone Biologics is a publicly traded company committed to developing and marketing orthobiologic products to enhance bone regeneration and repair in areas where current treatment options provide suboptimal outcomes. Their proprietary platform technology, NELL-1, is a recombinant human protein growth factor essential for normal bone development, and they are currently preparing for pilot clinical trials in Australia with potential commercialization into the $3 billion global orthobiologics market.

Bone Biologics fosters a culture of innovation and collaboration, driven by a shared commitment to advancing regenerative medicine for bone. The company values scientific rigor, teamwork, and a patient-centric approach, creating an environment where employees can contribute their expertise and work together to develop groundbreaking solutions for bone regeneration and repair.